Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma.
Authors
Dreyling, MMorschhauser, F
Bouabdallah, K
Bron, D
Cunningham, D
Assouline, S
Verhoef, G
Linton, Kim M
Thieblemont, C
Vitolo, U
Hiemeyer, F
Giurescu, M
Garcia-Vargas, J
Gorbatchevsky, I
Liu, L
Koechert, K
Peña, C
Neves, M
Childs, B
Zinzani, P
Affiliation
Department of Medicine, Klinikum der Universitat Munchen-Grosshadern, Medizinische Klinik und Poliklinihlk III, Munich, GermanyIssue Date
2017-06-14
Metadata
Show full item recordAbstract
Copanlisib is a pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor with predominant activity against the α- and δ- isoforms.Citation
Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. 2017 Ann OncolJournal
Annals of OncologyDOI
10.1093/annonc/mdx289PubMed ID
28633365Type
ArticleLanguage
enISSN
1569-8041ae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdx289
Scopus Count
Collections
Related articles
- Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.
- Authors: Dreyling M, Santoro A, Mollica L, Leppä S, Follows GA, Lenz G, Kim WS, Nagler A, Panayiotidis P, Demeter J, Özcan M, Kosinova M, Bouabdallah K, Morschhauser F, Stevens DA, Trevarthen D, Giurescu M, Cupit L, Liu L, Köchert K, Seidel H, Peña C, Yin S, Hiemeyer F, Garcia-Vargas J, Childs BH, Zinzani PL
- Issue date: 2017 Dec 10
- Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial.
- Authors: Matasar MJ, Capra M, Özcan M, Lv F, Li W, Yañez E, Sapunarova K, Lin T, Jin J, Jurczak W, Hamed A, Wang MC, Baker R, Bondarenko I, Zhang Q, Feng J, Geissler K, Lazaroiu M, Saydam G, Szomor Á, Bouabdallah K, Galiulin R, Uchida T, Soler LM, Cao A, Hiemeyer F, Mehra A, Childs BH, Shi Y, Zinzani PL
- Issue date: 2021 May
- Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study.
- Authors: Dreyling M, Santoro A, Mollica L, Leppä S, Follows G, Lenz G, Kim WS, Nagler A, Dimou M, Demeter J, Özcan M, Kosinova M, Bouabdallah K, Morschhauser F, Stevens DA, Trevarthen D, Munoz J, Rodrigues L, Hiemeyer F, Miriyala A, Garcia-Vargas J, Childs BH, Zinzani PL
- Issue date: 2020 Apr
- Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives.
- Authors: Munoz J, Follows GA, Nastoupil LJ
- Issue date: 2021 May
- A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial.
- Authors: Grunenberg A, Kaiser LM, Woelfle S, Schmelzle B, Viardot A, Möller P, Barth TFE, Muche R, Dreyhaupt J, Raderer M, Kiesewetter B, Buske C
- Issue date: 2021 Jun 29